CK7, CK20, and CDX2 Refine Prognosis in Small Intestinal Adenocarcinoma: Annals of Oncology | 2026
Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated June 1, 2026
- Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes.
- This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have prognostic value in SIA.
- The analysis included 691 patients with available biomarker data and was independently validated in a separate multicenter cohort.
- CK20 positivity was associated with significantly better overall survival.
- CDX2 positivity was also associated with improved survival, consistent with findings previously reported in colorectal and gastric cancers.
- In contrast, CK7 positivity identified a higher-risk subgroup with more aggressive clinical features.
- CK7-positive tumors were more likely to be:
Proximally located
Advanced stage at diagnosis
Microsatellite stable
- Loss of CK20 expression and loss of CDX2 expression were independent predictors of worse survival, even after adjustment for stage, treatment, age, sex, and tumor location.
- Combined CK7, CK20, and CDX2 expression profiles identified distinct prognostic categories with substantially different outcomes.
- Importantly, these markers are already widely available in routine pathology practice and require no additional molecular testing.
- The study demonstrates that immunohistochemistry can provide both diagnostic and prognostic information in SIA.
- The findings support incorporation of these markers into routine pathological reporting for small intestinal adenocarcinoma.
- Risk stratification based on CK7, CK20, and CDX2 may eventually help guide surveillance intensity, clinical trial enrollment, and treatment decision-making.
- Given the rarity of SIA, easily obtainable biomarkers are particularly valuable because large molecular datasets remain limited.
Bottom line: CK20 and CDX2 positivity identify favorable-prognosis small intestinal adenocarcinoma, whereas CK7 positivity marks a clinically important higher-risk subgroup. Routine assessment of these inexpensive immunohistochemical markers may significantly improve prognostic stratification in this rare malignancy.
